• Annual Report 2018


    Online Version

To our Shareholders

2018 was another eventful year for Fresenius. Many developments were positive and took us forward – I’ll tell you about the most important ones a little farther down. 2018 was also a successful business year for our company, as we set new records for sales and earnings – for the 15th straight year! We will, therefore, be proposing to the Annual General Meeting our 26th consecutive dividend increase.


Read more

Management Board

Pictured left to right   DR. ERNST WASTLER · CEO Fresenius Vamed       DR. FRANCESCO DE MEO · CEO Fresenius Helios       MATS HENRIKSSON · CEO Fresenius Kabi       STEPHAN STURM · Chairman of the Management Board       RACHEL EMPEY · Chief Financial Officer       DR. JÜRGEN GÖTZ · Chief Legal and Compliance Officer, and Labor Relations Director       RICE POWELL · CEO Fresenius Medical Care

Financial Highlights

Sales

33,530m

+6%1, 2

FY/17: €32,841 m2

Dividende3

0.80

+7%

FY/17: €0.75

EBIT4

4,561 m

-1%1

FY/17: €4,746 m

Employees

276,750

Dec. 31, 2017: 273,249

Net Income4

1,871 m

+7%1

FY/17: €1,804 m

Earnings per Share4

3.37

+6%1

FY/17: €3.26

1 In constant currency
2 Adjusted for IFRS 15 adoption and divestitures of Care Coordination activities
3 FY/18 Proposal
4 Before special items and after adjustments

  • Fresenius Medical Care

    Operating performance in 2018 was influenced by special items. We were able to increase the number of dialysis patients treated worldwide, further strengthening our market position.







  • Fresenius Kabi

    Our business grew across all regions and product segments in 2018. Organic sales growth of 7% and EBIT growth in constant currency of 2% significantly exceeded original expectations.







  • Fresenius Helios

    The business development in 2018 was a mixed picture. While preparatory measures for expected regulatory requirements and a decline in the number of admissions weighed on business at Helios Germany, Helios Spain continued to show dynamic growth.






  • Fresenius Vamed

    Our company developed very well in 2018 and achieved both its sales target and its earnings target, which had been increased in the course of the year. The acquisition of post-acute care facilities in Germany strengthens our service business. A strong order book secures future growth in the project business.






Group Management Report

The advantages of our diversified Group structure were clearly evident in fiscal year 2018. We achieved our Group sales and earnings targets for fiscal 2018.

Group Management Report

Group Non-Financial Report

We are committed to responsible management and ethical business principles as an integral part of the Fresenius corporate culture.

Group Non-Financial Report